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ABSTRACT
Background: Mammary tumors are frequent in female dogs, and are biologically similar in female dogs and humans. 
Hemostatic disorders are common in humans with cancer, and the mechanisms that conduct coagulation activation involve 
tissue and cancer procoagulant factors and inflammatory cytokines. Despite the importance of coagulopathy diagnosis that 
evaluate hemostasis, veterinarians rarely request such tests in routine clinical oncology. This study aimed to investigate the 
possible hemostatic abnormalities in female dogs with mammary carcinomas and assess any associations with prognostic 
factors for mammary cancer in female dogs. 
Materials, Methods & Results: A total of 62 female dogs were selected for inclusion in this study regardless of age or breed. 
The control group consisted of 30 healthy dogs, and the carcinoma group consisted of 32 dogs with a histopathological 
diagnosis of mammary carcinoma that was free of distant metastases and comorbidities that could interfere with the he-
mostatic system integrity. The dogs with mammary carcinoma were divided into subgroups according to their histological 
type, histopathological grading, tumor size, and clinical stage of the disease (TNM) to evaluate the relationships between 
the subgroups and hemostatic parameters (blood platelet counts, prothrombin time [PT], activated partial thromboplastin 
time [aPTT], and plasma fibrinogen concentration). The hemostatic parameters were significantly higher in the carcinoma 
group than in the control group (P ≤ 0.05). These findings indicate that there is a strong association between the occurrence 
of mammary carcinoma and abnormal hemostatic parameters, as well as a strong association between histopathological 
grade I and normal hemostatic parameters. In addition, when evaluating subgroups, PT and aPTT values were significantly 
higher in dogs with histopathological grade II and III tumors than in dogs with histopathological grade I tumors. Further-
more, PT and aPTT values were higher in the clinical stage IV subgroup than in the remaining subgroups. Nonetheless, 
there was no statistical difference in these values among the clinical stage I, III, and IV subgroups.
Discussion: Recent studies demonstrated that thrombocytosis is a common finding in dogs with cancer and that the true 
incidence of thrombocytosis might be underreported. The prolonged PT and aPTT observed in this study were higher 
than those described in the literature. The abnormalities in PT and aPTT values detected in female dogs with mammary 
carcinoma in this study might have been affected by the histopathological severity (grades II and III) and clinical disease 
stage. Hyperfibrinogenemia detected in the carcinoma group was the most common hemostatic abnormality. This finding 
was close to that found in the literature, in which 66.7% of female dogs presented with high fibrinogen values, which was 
more evident in dogs of clinical disease stages III and IV. The results indicate that 56% of animals presented with at least 
three hemostatic abnormalities, including the prolongation of PT and aPTT and hyperfibrinogenemia. These abnormalities 
were related to advanced clinical stages and histopathological grades II and III. Thus, the observed abnormalities can be 
indicative of a poorer prognosis and survival time of these patients because the previously identified products of coagula-
tion are important for both tumor dissemination and progression.
Keywords: mammary neoplasia, dogs, coagulopathies, platelets, fibrinogen.
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INTRODUCTION
Hemostatic abnormalities are common in hu-
mans [1] and dogs with cancer [5,15] and significantly 
contribute to the morbidity and mortality rates of this 
illness [13]. There is a strong association between 
malignant disease and the occurrence of hemostatic ab-
normalities, including thrombosis, in humans [10,13].
The pathogenesis of hemostatic disorders 
associated with malignant neoplasms is complex 
and multifactorial [10,12,13]. The important role of 
platelets and coagulation and fibrinolysis proteins on 
tumor growth and progression has been reported [2]. 
Malignant cells are capable of activating hemostasis 
[25] and the same oncogenes responsible for neoplastic 
cell transformation [16] enhance this phenomenon.
Cancer patients typically present with abnor-
mal results on hemostasis evaluation laboratory tests. 
Previous findings indicated that fibrin formation and 
degradation was parallel to the development of malig-
nancy, which suggests that fibrin and other coagulation 
products are important for both tumor thrombogenesis 
and progression [13]. Human patients with malignant 
diseases can develop arterial thrombosis and dissemi-
nated intravascular coagulation (DIC), followed by se-
vere hemorrhage. Therefore, it is of extreme clinical 
importance to prevent such complications, because they 
contribute considerably to the patient’s prognosis [12].
The objective of this study was to investigate 
possible hemostatic abnormalities in female dogs with 
mammary carcinoma, and assess the associations of 
such abnormalities with known prognostic factors for 
female breast cancer.
MATERIALS AND METHODS
Animals
A total of 62 female dogs were included in 
this study, regardless of age or breed. The control 
group consisted of 30 dogs that were free of mam-
mary neoplasia and presented with clinically healthy 
laboratory parameters within the reference intervals 
for the species. Thus, 32 female dogs with a diagnosis 
of mammary carcinoma determined by histopatho-
logical examination, that were confirmed to be free 
of distant visible metastases by conventional methods 
of three-dimensional analysis of thoracic radiographs 
and abdominal ultrasonography, were included as the 
experimental (carcinoma) group. Female dogs pre-
senting with comorbidities or those receiving medica-
tions that could interfere with the hemostatic system 
integrity were excluded. Animals were recruited from 
the Obstetrics and Oncology Division of Governador 
Laudo Natel Veterinarian Hospital - FCAV-UNESP 
and from Veterinarian Hospital Unit of Moura Lacerda 
University Center, Ribeirão Preto  SP Campus. All dogs 
underwent laboratory tests (blood count, creatinine, 
and alanine aminotransferase testing). Female dogs 
with mammary carcinoma were classified according 
to the clinical stage (I-IV), as proposed by Cassali et 
al. [4]. In addition, epithelial tumors were classified 
by specific histopathological criteria based on Elston 
and Ellis’s [9] classification system to determine pos-
sible associations with hemostatic parameters (platelet 
count, PT, aPTT, and plasma fibrinogen concentration). 
Blood sampling
All female dogs with mammary neoplasia 
were submitted to a mastectomy mammary chain and 
histopathological examination. Blood samples were 
collected before the surgical procedure. Animals 
underwent blood collection by means of jugular veni-
puncture with the aid of hypodermic needles (25× 0.8 
mm) and 5 mL syringes. The initial 4 mL of blood was 
collected in a tube containing sodium chloride citrate 
anticoagulation at 3.2% for hemostatic testing, and 
the remaining 1 mL of blood was decanted into tubes 
containing 7.2 mg of ethylenediamine tetra-acetic di-
potassium anticoagulant acid (K2EDTA) to determine 
the platelet counts. 
Tubes containing blood samples with K2EDTA 
were immediately processed and analyzed, whereas 
tubes containing blood samples with sodium citrate 
were centrifuged at 1,260 g for 30 min at 4°C. Later, 
the citrated plasma was split into fractions and stored 
in labeled micro tubes at -80°C until analysis of the 
fibrinogen concentration, PT, and aPTT.
Blood sample processing
Hemostatic tests were performed at the Pathol-
ogy Laboratory at the “Prof. Joaquim Martins Ferreira 
Neto” Veterinarian Clinic in Governador Laudo Natel 
Veterinarian Hospital – FCAV-UNESP, and at the 
Veterinarian Hospital Unit of Moura Lacerda Univer-
sity Center, Ribeirão Preto Campus, SP. The blood 
collected in tubes with K2EDTA was homogenized, 
and the global platelet count was assessed using an 
automatic blood cell counter (ABC VetCounter)1.
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To determine the PT, aPTT, and plasma fibrino-
gen concentration, the citrate plasma aliquots were thawed 
to 22 ± 2°C, and the analyses were conducted immediately 
according to the coagulometer manufacturer’s guidelines 
(Quick Timer II)2. The model establishes the coagulation 
time of a blood plasma sample (150 µL) using an optical 
system to detect sudden optical density variation in the 
sample, at the coagulation moment. Sets of commercial 
reagents3 were used to determine such variations. All 
samples were double analyzed. The PT and aPTT refer-
ence limits were determined from the mean values of the 
control group and were considered to be altered when the 
difference was greater than 5 s of the mean. The platelet 
and fibrinogen reference limits were determined from lo-
cal reference values (Laboratory of Veterinarian Clinical 
Pathology of FCAV/UNESP - Jaboticabal).
Statistical analysis
The Kolmogorov-Smirnov test for normality 
was used to evaluate the data normality. A Student’s 
t-test was applied to compare the means of the hemo-
static parameters between the control group and the 
carcinoma group. An analysis of variance was used 
to compare hemostatic parameters (platelet counts, 
PT, aPTT, and fibrinogen concentration) among the 
different subgroups evaluated (histopathological type 
and grading, clinical disease stage, and tumor size). 
Tukey’s multiple comparison test was used to deter-
mine the differences among the mean values of the 
hemostatic parameters. The analyses were performed 
using R Software with a significance level (α) of 5%. 
Multiple correspondence analysis (MCA) using the 
Chi squared test (χ²) was used to evaluate the pos-
sible associations among the hemostatic parameters 
and the different groups and subgroups of female 
dogs with mammary carcinoma. Values > 1.9 indicate 
highly meaningful categories, and values < 1.9 indi-
cate weakly meaningful categories. MCA statistical 
analyses were performed using Statistica 7® software
RESULTS
Significant differences were detected in all 
hemostatic parameters evaluated in this study (plate-
let counts, PT, aPTT, and fibrinogen concentration) 
between the carcinoma and control groups (Table 1). 
The blood platelet count was significantly higher in the 
carcinoma group than in the control group. In addition, 
the blood platelet count was above the reference limit 
value (400 ×103/µL) for the species in 46% (n= 15) 
of the dogs with mammary carcinoma. However, there 
was no significant difference in the platelet counts 
among the subgroups (Table 2).
The mean plasma fibrinogen concentration was 
also significantly higher in the carcinoma group than in 
the control group (Table 1). Hyperfibrinogenemia (> 300 
mg/dL) was observed in 65.6% (n= 21) of the sick indi-
viduals. In the evaluation of subgroups in Table 2, dogs 
with histopathological grade II and III presented with 
significantly higher fibrinogen concentration values  than 
those of dogs with grade I tumors. Regarding clinical 
staging, dogs with stage IV carcinoma presented with the 
highest mean fibrinogen value, which was significantly 
higher than those of dogs with stage I and II carcinoma.
The mean PT and aPTT values were signifi-
cantly higher in the carcinoma group than in the control 
group (Table 1). Evaluation of the subgroups (Table 2) 
revealed that the PT and aPTT values were higher in 
dogs with histopathological grade II and III tumors than 
in those with grade I tumors. With regard to the clini-
cal stage, the PT and aPTT values were significantly 
higher in dogs with stage IV carcinoma than in dogs 
with stage II carcinoma. The evaluation of tumor size 
indicated that dogs with tumors of 3-5 cm in diameter 
presented with significantly lower aPTT values than 
did the dogs with other tumor sizes. In the histopatho-
logical subgroup analysis, no meaningful differences 
were observed in the PT and aPTT values (Table 2).
Perceptual mapping indicated two groups that 
contained both interrelating and contrasting categories 
(Figure 1), and four groups of interrelating categories 
(Figure 2).
Figure 1. Perceptual mapping of the hemostatic parameters in the control 
and carcinoma group. The parameters presented in the map are platelets 
(Plat), prothrombin time (PT), activated partial thromboplastin time 
(aPTT), and fibrinogen (Fibri). Rectangles represent strong associations. 
The perceptual mapping quality was 89.12% (dimension 1: 72.59% and 
dimension 2: 16.53%).
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Figure 2. Perceptual mapping of the hemostatic parameters (Plat, PT, aPTT and Fibri) obtained 
among in the subgroups studied (Histopathological Type mixed, papillary, tubular, others; 
Clinical Staging I_II, III, IV; Histopathological Degree G_I, G_II, G_III and tumor size T ≤ 
3 and T≥3). Rectangles represent strong associations and circles represent weak associations. 
The perceptual mapping quality was 49.06% (dimension 1: 29.63% and dimension 19.43%).
Table 1. Comparison of the hemostatic parameters (platelets count, prothrombin time, activated partial thrombo-
plastin time and fibrinogen concentration) in the control (healthy) and mammary carcinoma groups (diseased).
Parameter
Groups
Control Carcinoma
Platelets (x103)/µL 299.5 ± 99.1b 417.7 ± 166.2a
PT (s) 6.5 ± 0.9b 15.2 ± 7.1a
aPTT (s) 9.2 ± 1.6b 20.2 ± 10.3a
Fibrin (mg/dL) 251.4 ± 32.8b 385.0 ± 136.0a
Mean values of the hemostatic parameters a,bDifferent characters indicate significant differences (P ≤ 0.05) 
between the two groups. PT = prothrombin time, aPTT = activated partial thromboplastin time.
DISCUSSION
The conducting mechanisms that activate the 
hemostatic system in patients with cancer involve tis-
sue and cancer pro-coagulant factors and inflammatory 
cytokines [25]. However, it is well established that 
hemostatic compounds such as platelets and coagula-
tion and fibrinolysis proteins play important roles in 
tumor growth and progression [2]. 
 In this study, the platelet count was higher 
in the carcinoma group than in the control group. 
Thrombocytosis is a rare condition in dogs with ma-
lignant neoplasia [5], but typically occurs in humans 
with cancer [6]. However, there ports presented in the 
literature are conflicting, as some authors suggest that 
thrombocytopenia is the most common abnormality in 
dogs with malignant disease [5], while others indicate 
that thrombocytosis is a frequent abnormality in dogs 
with cancer [18,21,27]; thus, the true prevalence of 
thrombocytosis in animals with neoplasia might be 
underreported [5].
Thrombocytosis is associated with the state of 
hypercoagulability that follows cancer and with poor 
prognosis in human patients [14,24]. The mechanism 
underlying thrombocytosis in patients with neoplasia 
has not been fully elucidated, but it has been suggested 
that this disorder is due to the release of proangiogenic 
tumor factors and inflammatory cytokines (interleukin 
[IL]-1 and [IL]-6) or the hematopoietic growth factors 
[5,21] expelled or induced by the tumor.
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Table 2. Platelet count, prothrombin time, activated partial thromboplastin time, and fibrinogen concentration among the subgroups of the female 
dogs with mammary carcinoma (histopathological grade, clinical staging and tumor size).
Carcinoma
Platelets
 (x103)/µL
PT (s)   aPTT (s)  Fibrin (mg/dL)
Histopathological Type     
Adenomyoepithelioma Malignant 375.5 ± 38.9a 11.6 ± 10.7a 16.6 ± 15.3a 396 ± 148.5a
Mixed tumor carcinoma 421.6 ± 130.8a 14.5 ± 6.6a 19.2 ± 8.4a 353.4 ± 125.3a
Papillary carcinoma 458.2 ± 226.6a 19.4 ± 7.5a 25.9 ± 9.7a 481.2 ± 124.7a
Solid carcinoma 339.7 ± 170.2a 20.3 ± 10.8a 29.2 ± 15.9a 523.3 ± 196.1a
Tubular carcinoma 425.1 ± 219.8a 12.7 ± 5.3a 16.1 ± 9.6a 325.6 ± 94.5a
Histopathological Grading     
Grade 1 424.8 ± 164.6a 9.2 ± 4.4b 12.2 ± 6.2b 292.0 ± 86.1b
Grade 2 444.6 ± 132.7a 18.9 ± 5.9a 23.4 ± 7.8a 427.6 ± 129.2a
Grade 3 358.3 ± 224.9a 19.9 ± 5.4a 29.7 ± 9.4a 484.7 ± 127.4a
Clinical Staging     
Stage I 382.9 ± 158.8a 14.3 ± 5a, b 18.4 ± 6.8a, b 338.1 ± 88.1b
Stage II 502.8 ± 246.4a 8.1 ± 5.4b 8.5 ± 4.4b 301.3 ± 58.4b
Stage III 449.9 ± 170.1a 15.2 ± 8.6a,b 20.6 ± 10.9a, b 372.4 ± 165a, b
StageIV 406.4 ± 140.7a 21.1 ± 6.6a 30.3 ± 10a 539.3 ± 110a
Tumor size     
Size < 3 cm 382 ± 158.1a 15.3 ± 5.8a 21.1 ± 9.8a 367.8 ± 117.9a
Size 3-5 cm 502.8 ± 246.4a 8.1 ± 5.4a 8.5 ± 4.4b 301.3 ± 58.4a
Size > 5 cm 436.8 ± 149.3a 17.3 ± 8.2a 23 ± 10a 435.8 ± 162.7a
Mean values of the hemostatic parameters in the subgroups. a,bDifferent characters indicate significant differences (P ≤ 0.05) between the evaluated 
groups. PT = prothrombin time, aPTT = activated partial thromboplastin time.
Prolongation of PT and aPTT was observed in 
62.5% of the dogs in the carcinoma group, and this re-
sult is superior to that reported by Stockhaus et al. [22]. 
This study demonstrated a strong association between 
the presence of carcinoma and the evaluated hemostatic 
parameters (Figure 1), and found significant differ-
ences between the two groups (Table 1). The current 
results are in contrast to those of the study conducted 
by Saavedra et al. [21], where in no meaningful dif-
ferences in PT and aPTT were observed between dogs 
with carcinoma and the control group. 
The hemostatic abnormalities identified in 
female dogs with mammary carcinoma in this study 
might have been affected by the histopathological 
grade and clinical stage of the disease. Therefore, these 
characteristics are associated with more aggressive 
tumor malignancy, and likely to greater induction of 
inflammatory cytokines, which can promote increases 
in the levels of coagulation factors [1]. However, the 
exact causes of coagulation abnormalities remain un-
known. Thus, the present result suggests that the actual 
incidence of hemostatic abnormalities in animals with 
neoplasia might be underestimated. 
The present study indicates that female dogs 
in clinical stages I, III, and IV exhibited higher PT and 
aPTT values. The abnormalities observed in dogs at 
stages III and IV corroborate the findings of the study 
by Stockhaus et al. [22], in which prolongation of PT 
and aPTT was also observed in dogs at the same disease 
stages. However, such abnormalities were not expected 
at stage I. The fact that such animals present with 
moderately differentiated (histopathological grade II) 
and slightly differentiated (histopathologicalgrade III) 
tumors might explain the results. These grades indicate 
greater tumor aggression and malignancy, thereby 
justifying the abnormalities observed in the hemostatic 
parameters (aPTT, PT, and fibrinogen concentration) 
[Table 2]. A strong association was observed between 
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histopathological grade I and hemostatic parameters 
(aPTT, PT, and fibrinogen concentration) within the 
normal range (Figure 2), indicating that the female 
dogs with mammary carcinoma grade I did not present 
with coagulation abnormalities and were similar to the 
dogs in the control group.
Hyperfibrinogenemia is common in dogs with 
malignant disease [26], and was the most frequent 
hemostatic abnormality found in this study; 65% of 
female dogs with mammary carcinoma presented 
with hyperfibrinogenemia. The prevalence increased 
according to the progression of the illness, and was 
more evident in dogs at disease stages III and IV, as 
well as in dogs with highly aggressive tumors of his-
topathological grades II and III. This result is similar 
to that previously reported [7], in which 66.7% of the 
female dogs presented with high fibrinogen values 
that became more evident in dogs at stages III and IV.
Despite the increasing levels of fibrinogen with 
disease progression in female dogs with mammary 
carcinoma, the correlation between the fibrinogen con-
centration and tumor progression remains controversial 
and unclear [19,21,22]. However, hyperfibrinogenemia 
has previously been associated with cancer progression 
in human patients [20] and canine patients [1]. In addi-
tion, 61% of dogs with carcinoma and hypercoagula-
bility were found to present with increased fibrinogen 
levels, thus indicating the effect of the fibrinogen on 
hypercoagulability [21].
DIC was reported in ≤ 10% of dogs with solid 
tumors [21] and has been identified in female dogs with 
mammary carcinoma [17]. DIC diagnosis is based on 
the presence of at least three abnormalities including 
thrombocytopenia; prolongation of PT, aPTT, and 
thrombin time; hyperfibrinogenemia; and increases in 
the products of fibrin degradation and D-dimerization 
[3,22,23]. However, none of the dogs included in this 
study were diagnosed with DIC. Nonetheless, it is 
important to mention that 56% of the animals in this 
study presented with at least three coagulation ab-
normalities including PT and aPTT prolongation and 
hyperfibrinogenemia. This indicates that female dogs 
with mammary carcinoma may present with blood 
coagulation abnormalities without apparent clinical 
manifestations of thrombosis or hemorrhage. Thus, 
the current study demonstrates the importance of the 
evaluation of hemostasis in female dogs with mam-
mary carcinoma.
CONCLUSIONS
In conclusion, the majority of female dogs 
with mammary carcinoma presented with abnormali-
ties on blood coagulation laboratory tests, and such 
abnormalities were influenced by the histopathologi-
cal grade and clinical disease stage. Hyperfibrinogen-
emia was the most common abnormality in female 
dogs with mammary carcinoma and seems to be 
related to disease progression. The increases in the 
platelet count, fibrinogen concentration, PT, and aPTT 
might be associated with a pro-inflammatory response 
induced by the tumor and are indicative of a state of 
hyperfibrinogenemia.
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